ATAI Life Sciences NV (9VC) - Total Assets
Based on the latest financial reports, ATAI Life Sciences NV (9VC) holds total assets worth €239.82 Million EUR (≈ $280.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 9VC operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
ATAI Life Sciences NV - Total Assets Trend (2019–2024)
This chart illustrates how ATAI Life Sciences NV's total assets have evolved over time, based on quarterly financial data. See 9VC net asset value for net asset value and shareholders' equity analysis.
ATAI Life Sciences NV - Asset Composition Analysis
Current Asset Composition (December 2024)
ATAI Life Sciences NV's total assets of €239.82 Million consist of 50.3% current assets and 49.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.0% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.25 Million | 2.0% |
| Goodwill | €331.00K | 0.2% |
Asset Composition Trend (2019–2024)
This chart illustrates how ATAI Life Sciences NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 9VC stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ATAI Life Sciences NV's current assets represent 50.3% of total assets in 2024, a decrease from 63.0% in 2019.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2024, down from 48.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2.0% of total assets.
ATAI Life Sciences NV Competitors by Total Assets
Key competitors of ATAI Life Sciences NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
ATAI Life Sciences NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.90 | 5.81 | 17.92 |
| Quick Ratio | 7.90 | 5.81 | 17.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €114.12 Million | €94.43 Million | €354.15 Million |
ATAI Life Sciences NV - Advanced Valuation Insights
This section examines the relationship between ATAI Life Sciences NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.19 |
| Latest Market Cap to Assets Ratio | 8.00 |
| Asset Growth Rate (YoY) | -45.7% |
| Total Assets | €159.39 Million |
| Market Capitalization | $1.27 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values ATAI Life Sciences NV's assets at a significant premium (8.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: ATAI Life Sciences NV's assets decreased by 45.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ATAI Life Sciences NV (2019–2024)
The table below shows the annual total assets of ATAI Life Sciences NV from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €159.39 Million ≈ $186.34 Million |
-45.69% |
| 2023-12-31 | €293.48 Million ≈ $343.11 Million |
-3.92% |
| 2022-12-31 | €305.44 Million ≈ $357.09 Million |
-26.25% |
| 2021-12-31 | €414.17 Million ≈ $484.20 Million |
+271.29% |
| 2020-12-31 | €111.55 Million ≈ $130.41 Million |
+79.58% |
| 2019-12-31 | €62.12 Million ≈ $72.62 Million |
-- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more